Who Achieves Minimal and Very Low Disease Activity in Psoriatic Arthritis? An Analysis of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

A. Ogdie, MD, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
C. Song, PhD, UCB, Smyrna, GA, USA.
N. Middaugh, ScD, Thermo Fisher Scientific, Waltham, MA, USA.
M. Marchese, MS, Thermo Fisher Scientific, Waltham, MA, USA.
M. Eliot, PhD, Thermo Fisher Scientific, Waltham, MA, USA.
R. Low, PharmD, UCB, Smyrna, GA, USA.
P.J. Mease, MD, Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, USA.

Contributions: All authors made substantial contributions to study conception or design, or acquisition, analysis, and interpretation of the data, and drafted the article or reviewed it critically for important intellectual content. All authors gave final approval of the version of the article to be published and agreed to be accountable for all aspects of the article.
Funding: This study was sponsored by the PPD™ clinical research business of Thermo Fisher Scientific, and the analysis was funded by UCB. Access to study data was limited to PPD™ CorEvitas™ Clinical Registries and CorEvitas statisticians completed all the analyses. CorEvitas has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eli Lilly and Company, Genentech, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Inc., Sun Pharmaceutical Industries, Ltd., and UCB. Support for third-party writing assistance for this article, provided by Lauren Konieczynski, BS of Costello Medical, Boston, MA, USA and Kaity McCafferty Layte, BS of Mac Medical Communications, London, UK, was funded by UCB in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.ismpp.org/gpp-2022).
Competing interests: AO: Grants from Amgen, AbbVie, BMS, Janssen, Novartis, and Pfizer, Inc.; consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CorEvitas, LLC, Eli Lilly and Company, Janssen, GSK, Gilead, MoonLake Immunotherapeutics, Merck, Novartis, Pfizer, Inc., Spyre, Takeda, and UCB. CS, RL: Employees and shareholders of UCB. NM, MM, ME: Employees of Thermo Fisher Scientific, Inc. PJM: Research grants from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Johnson & Johnson Innovative Medicine, Novartis, Pfizer, Inc., Sana, and UCB; consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Century, Cullinan, Eli Lilly and Company, Inmagene, Johnson & Johnson Innovative Medicine, MoonLake Immunotherapeutics, Novartis, Pfizer, Inc., Spyre, Takeda, and UCB; speakers bureau fees from AbbVie, Amgen, Eli Lilly and Company, Johnson & Johnson Innovative Medicine, Novartis, Pfizer, Inc., and UCB.
Ethics and patient consent: The study was performed in accordance with the Declaration of Helsinki. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), the New England Independent Review Board (NEIRB; no. 120160939). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC before the site's participation and initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization before participating.

Correspondence to: Dr. Philip J. Mease (pmease{at}philipmease.com) Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, USA